| |
| | [Clinical Preventive Services] Screening for Neural Tube Defects -- Including Folic Acid/Folate Prophylaxis (Site not responding. Last check: 2007-11-03) |
 | | The birth prevalence of neural tube defects has declined substantially over the past 60 years.3,4 Neural tube defects are reported in 3.6-4.6/ 10,000 live births in the United States.3,5 These rates underestimate true incidence, however, because affected pregnancies may be spontaneously or electively aborted and because not all cases are detected and reported at birth. |
 | | Of eight neural tube defects occurring in the screened group, seven were detected by screening and electively aborted, reducing the birth prevalence by 88%, to 0.13/1,000 screened women. |
 | | While MSAFP screening is a relatively safe procedure, neural tube defects are relatively uncommon, and in certain low-prevalence populations it is possible for the complication rate from screening and its follow-up diagnostic tests to equal or exceed the detection rate for the target condition. |
| cpmcnet.columbia.edu /texts/gcps/gcps0052.html (5236 words) |
|